J Frazer1, S Couban1,2, S Doucette3, S Shivakumar1,2. 1. Faculty of Medicine, Dalhousie University, and. 2. Division of Hematology, Department of Medicine, and. 3. Research Methods Unit, Department of Community Health and Epidemiology, QEII Health Sciences Centre, Halifax, NS.
Abstract
BACKGROUND: Allogeneic hematopoietic stem-cell transplantation (ahsct) is associated with significant morbidity and mortality, but it can cure carefully selected patients with acute myeloid leukemia (aml) in second remission (cr2). In a cohort of patients with aml who underwent ahsct in cr2, we determined the pre-transplant factors that predicted for overall survival (os), relapse, and non-relapse mortality. We also sought to validate the prognostic risk groups derived by Michelis and colleagues in this independent population. METHODS: In a retrospective chart review, we obtained data for 55 consecutive patients who underwent ahsct for aml in cr2. Hazard ratios were used to describe the independent effects of pre-transplant variables on outcome, and Kaplan-Meier curves were used to assess outcomes in the three prognostic groups identified by Michelis and colleagues. RESULTS: At 1, 3, and 5 years post-transplant, os was 60%, 45.5%, and 37.5% respectively. Statistically significant differences in os, relapse mortality, and non-relapse mortality were not identified between the prognostic risk groups identified by Michelis and colleagues. Women were less likely than men to relapse, and a modified European Society for Blood and Marrow Transplantation (mebmt) score of 3 or less was associated with a lower non-relapse mortality. CONCLUSIONS: The 37.5% 5-year os in this cohort suggests that, compared with other options, ahsct offers patients with aml in cr2 a better chance of cure. Our study supports the use of the mebmt score to predict non-relapse mortality in this population.
BACKGROUND: Allogeneic hematopoietic stem-cell transplantation (ahsct) is associated with significant morbidity and mortality, but it can cure carefully selected patients with acute myeloid leukemia (aml) in second remission (cr2). In a cohort of patients with aml who underwent ahsct in cr2, we determined the pre-transplant factors that predicted for overall survival (os), relapse, and non-relapse mortality. We also sought to validate the prognostic risk groups derived by Michelis and colleagues in this independent population. METHODS: In a retrospective chart review, we obtained data for 55 consecutive patients who underwent ahsct for aml in cr2. Hazard ratios were used to describe the independent effects of pre-transplant variables on outcome, and Kaplan-Meier curves were used to assess outcomes in the three prognostic groups identified by Michelis and colleagues. RESULTS: At 1, 3, and 5 years post-transplant, os was 60%, 45.5%, and 37.5% respectively. Statistically significant differences in os, relapse mortality, and non-relapse mortality were not identified between the prognostic risk groups identified by Michelis and colleagues. Women were less likely than men to relapse, and a modified European Society for Blood and Marrow Transplantation (mebmt) score of 3 or less was associated with a lower non-relapse mortality. CONCLUSIONS: The 37.5% 5-year os in this cohort suggests that, compared with other options, ahsct offers patients with aml in cr2 a better chance of cure. Our study supports the use of the mebmt score to predict non-relapse mortality in this population.
Authors: Margaret R O'Donnell; Camille N Abboud; Jessica Altman; Frederick R Appelbaum; Daniel A Arber; Eyal Attar; Uma Borate; Steven E Coutre; Lloyd E Damon; Salil Goorha; Jeffrey Lancet; Lori J Maness; Guido Marcucci; Michael M Millenson; Joseph O Moore; Farhad Ravandi; Paul J Shami; B Douglas Smith; Richard M Stone; Stephen A Strickland; Martin S Tallman; Eunice S Wang; Maoko Naganuma; Kristina M Gregory Journal: J Natl Compr Canc Netw Date: 2012-08 Impact factor: 11.908
Authors: Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf Journal: Blood Date: 2006-02-02 Impact factor: 22.113
Authors: Dimitri A Breems; Wim L J Van Putten; Peter C Huijgens; Gert J Ossenkoppele; Gregor E G Verhoef; Leo F Verdonck; Edo Vellenga; Georgine E De Greef; Emanuel Jacky; Johannes Van der Lelie; Marc A Boogaerts; Bob Löwenberg Journal: J Clin Oncol Date: 2005-01-04 Impact factor: 44.544
Authors: Yves Chalandon; Michael J Barnett; Douglas E Horsman; Eibhlin A Conneally; Stephen H Nantel; Thomas J Nevill; Janet Nitta; John D Shepherd; Heathe J Sutherland; Cynthia L Toze; Donna E Hogge Journal: Biol Blood Marrow Transplant Date: 2002 Impact factor: 5.742
Authors: H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas Journal: Am J Med Date: 1980-08 Impact factor: 4.965
Authors: Julia-Annabell Georgi; Sebastian Stasik; Martin Bornhäuser; Uwe Platzbecker; Christian Thiede Journal: Front Oncol Date: 2022-02-17 Impact factor: 6.244
Authors: Mahshid Mehdizadeh; Vahid Bolourian; Gholamreza Zamani; Maria Tavakoli-Ardakanii; Shayan Zamani; Mahdi Tabarraee; Abbas Hajifathali Journal: Int J Hematol Oncol Stem Cell Res Date: 2022-01-01